I reckon if the rapid testing business goes well (and for the next 2-3 yrs if tech works no reason it wouldn’t go well) it’s worth 1.5-2$ per share, which is call it $600-800m mcap (I mean look at ADO as nearest comp). Add on that the track and trace and anti counter, PPE etc we could have here conservatively 3-4$ per share. I think once company has established validation of the tech via few initial sales we should have a very strong re rating.
Dotz Nano Vs Covid 19, page-222
-
- There are more pages in this discussion • 294 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add DTZ (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
9.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $51.50M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 585 | 10.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 9.2¢ | 58 | 1 |
View Market Depth
| Last trade - 09.17am 04/11/2024 (20 minute delay) ? |
| DTZ (ASX) Chart |
Day chart unavailable